House Energy & Commerce subcommittee Chair Michael Burgess (R-TX) has quietly introduced a bill that would eliminate the cap on Medicaid rebates that Obamacare created. The idea, included in the Trump administration's drug-pricing blueprint, has been criticized by the drug industry. The policy shift is supported by advocates for lower drug prices and insurers, but is also likely to pit two of Burgess' largest donors against each other. The Affordable Care Act capped the amount of rebates drug makers must...